{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'S', 'Assessment of total IgE, antigen-specific IgE, antigen-specific l IgG4, and ratio of IgE:lgG4.', 't', 'Systemic drug concentration samples are to be collected prior to dosing and in case of SAE and AESI.', 'u', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast of 1 hour.', 'I', 'W', 'ADA samples are to be collected prior to dosing and in case of SAE and AESI.', 'X', 'For female patients who have commenced menstruating (ie, are of child-bearing potential) at Screening, a urine pregnancy test is mandatory at the Screening Visit 1 with negative result obtained prior to', 'randomization at Visit 2 (Week 0) and at every subsequent visits defined in the flowchart. For female patients who happen to commence menstruating after Screening, a negative urine dipstick pregnancy test will', 'be obtained prior to administration of IMP.', 'y', 'Hematology: hemoglobin, hematocrit, platelet count, total white blood cell (WBC) count with five-part differential count, and total red blood cell count. Serum chemistry: creatinine, blood urea nitrogen, glucose, uric', 'acid, total cholesterol, total protein, albumin, total bilirubin (in case of values above the normal range, differentiation in conjugated and non-conjugated bilirubin), alanine aminotransferase, aspartate', \"aminotransferase, alkaline phosphatase, lactate dehydrogenase, electrolytes (sodium, potassium, chloride), bicarbonate, and creatine phosphokinase. Patients' fasting (considering fasting as no intake of any food\", 'or drink except for water for at least 8 hours) or non-fasting status at blood sample collection will be recorded on the Central Laboratory Requisition Form. Clinical laboratory testing only at Screening Visit 1 will', 'include hepatitis screen covering hepatitis B surface antigen (HBs Ag), hepatitis B surface antibody (HBs Ab), hepatitis B core antibody (HBc Ab), hepatitis C virus antibodies (HCV Ab), Human Immunodeficiency', 'Virus (HIV) screen (Anti-HIV-1 and HIV-2 antibodies) and anti-nuclear antibody (ANA).', 'Z', \"At Screening, parent(s)/caregiver(s)/legal guardian(s) will be asked to provide information on their child's vaccination schedule, and assess whether immunizing their children with any vaccination for tetanus,\", 'diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza (as per local medical practice) will result in vaccination during the study.', 'The timing of these vaccinations should be adjusted to fit into the IMP treatment period if appropriate. Any planned tetanus, diphtheria and pertussis vaccination should be administered between Visit 12 (Week 20)', 'and Visit 18 (Week 32), as administration after Visit 18 (Week 32) may require an additional blood draw (refer to Section 9.3.1.2) for assessment. Any planned seasonal trivalent/Quadrivalent influenza should be', 'administered between Visit 6 (Week 8) and Visit 18 (Week 32) as administration after Visit 18 (Week 32) may require an additional blood draw (refer to Section 9.3.1.2) for assessment.', 'aa Scheduled blood sample collection for pre-and post-vaccine antibody titers (ie, for IgG response assessment), for both vaccinations (ie, any tetanus, diphtheria and pertussis and/or seasonal trivalent/quadrivalent', 'influenza) should be drawn within 8 weeks prior to vaccination and at 3-4 weeks (up to 6 weeks) after the respective vaccination(s); however, all blood titer samples must be drawn between Week 6 and Week 50', '(ie, Visit 5 and Visit 27, respectively).', \"Depending on patient's vaccination schedule during the course of this study, every effort should be made to draw pre-vaccination titers at either Weeks 6, 12, or 24 (V5, V8, V14) of the Randomized Treatment\", 'Period, and to draw post-vaccination titers at either Weeks 12, 24, or 36 (V8, V14, V20) of the Randomized Treatment Period.', 'For patient(s) requiring urgent/emergency vaccination with any seasonal trivalent/quadrivalent influenza and/or any tetanus, diphtheria and pertussis vaccine (eg, flu season approaching, animal bite, emergency', 'room standard procedures) please refer to Section 9.3.1.2.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583 6.0', 'Page 25']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '2', 'TABLE OF CONTENTS', 'AMENDED CLINICAL TRIAL PROTOCOL 03', '1', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', '3', 'DOCUMENT HISTORY', '3', 'OVERALL RATIONALE FOR THE AMENDMENT', '3', '1', 'FLOW CHARTS', '20', '1.1', 'OVERVIEW OF STUDY DESIGN', '20', '1.2', 'STUDY FLOW CHART', '21', '2', 'TABLE OF CONTENTS', '26', '2.1', 'LIST OF TABLES', '33', '3', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '34', '4', 'INTRODUCTION AND RATIONALE', '37', '4.1', 'RATIONALE', '37', '4.2', 'RATIONALE FOR DOSE SELECTION', '38', '5', 'STUDY OBJECTIVES', '41', '5.1', 'PRIMARY', '41', '5.2', 'SECONDARY', '41', '5.3', 'OTHER', '41', '6', 'STUDY DESIGN', '42', '6.1', 'DESCRIPTION OF THE STUDY', '42', '6.2', 'DURATION OF STUDY PARTICIPATION', '42', '6.2.1', 'Duration of study participation for each patient', '42', '6.2.2', 'Determination of end of clinical trial (all patients)', '42', '6.3', 'INTERIM ANALYSIS', '42', '6.4', 'STUDY COMMITTEES', '42', '6.4.1', 'Data Monitoring Committee', '42', 'Property of the Sanofi Group - strictly confidential', 'Page 26', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}